Open AccessInfluence and mechanism of lung cavitation development on antiangiogenic therapy
Author(s) -
Man Jiang,
Chuantao Zhang,
Dong Liu,
Yongjie Wang,
Hongmei Wang,
Tianjun Li,
Helei Hou,
Na Zhou,
Junmin Zhu,
Hongying Lv,
Chuanyu Zhang,
Bingliang Fang,
Xiaochun Zhang
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.07.01
Subject(s) - apatinib , medicine , lung cancer , cancer research , in vivo , oncology , adenocarcinoma , cancer , biology , microbiology and biotechnology
Antiangiogenic agent-treated patients usually develop cavitation in their lung lesions. The clinical significance of lung cavitation development during antiangiogenic therapy has not been determined yet. Herein, we evaluated the clinical outcomes of patients who developed tumor cavitation following apatinib treatment and explored the mechanisms.